Spyre Therapeutics (SYRE) announced scientific presentations at the European Gastroenterology Week, UEGW, Congress. “We are excited to share follow-up data out to six months from our Phase 1 study of SPY002, our potential best-in-class anti-TL1A agent in development for IBD. The data continue to show SPY002 is well tolerated, has a differentiated PK profile supporting quarterly or twice-yearly dosing, and suppresses free TL1A through 24 weeks,” said Josh Friedman, M.D., Ph.D., SVP of Clinical Development at Spyre. “Additionally, we are pleased to share new preclinical data demonstrating that each of our combination programs exhibit superior efficacy relative to constituent monotherapies in rodent TNBS-induced colitis models, providing additional validation for our ongoing SKYLINE-UC Phase 2 study.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics initiated with a Buy at Deutsche Bank
- Promising Developments and Strategic Trials Drive Buy Rating for Spyre Therapeutics
- Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial
- Strategic Growth and Innovation Drive Buy Rating for Spyre Therapeutics
- Buy Rating for Spyre Therapeutics: Promising AFFINITY Study Results in Autoimmune Disease Market